In April 2019 we learned that the FDA is allowing Zelnorm back on the market 12 years after there was an FDA-mandated Zelnorm recall.
From this April 3, 2019 Healio article, “FDA approves reintroduction of Zelnorm for IBS-C in certain women”, we get this significant point:
Sloan Pharmaceuticals [(the responsible drug company)], a subsidiary of U.S. WorldMeds, acknowledged in [a press release] that there remains an increased risk for cardiac events, including myocardial infarction and stroke, when using [Zelnorm (tegaserod)].
For more background on this recent development, you can read our October 2018 article, “Will FDA Allow Zelnorm To Return After 2007 Recall For Safety Reasons?“.
We close by asking whether the FDA did the right thing allowing Zelnorm back on the market and whether this 2019 “second” approval of Zelnorm a good idea as regards the matter of drug safety.[View article at original source]